DE69721007D1 - Senkung der heftigkeit einer host-versus-graft-reaktion durch unterdrueckung der hsp60 autoimmunitaet - Google Patents

Senkung der heftigkeit einer host-versus-graft-reaktion durch unterdrueckung der hsp60 autoimmunitaet

Info

Publication number
DE69721007D1
DE69721007D1 DE69721007T DE69721007T DE69721007D1 DE 69721007 D1 DE69721007 D1 DE 69721007D1 DE 69721007 T DE69721007 T DE 69721007T DE 69721007 T DE69721007 T DE 69721007T DE 69721007 D1 DE69721007 D1 DE 69721007D1
Authority
DE
Germany
Prior art keywords
hsp60
reducing
violence
suppressing
hsp60 autoimmunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69721007T
Other languages
English (en)
Other versions
DE69721007T2 (de
Inventor
R Cohen
Ohad Birk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE69721007D1 publication Critical patent/DE69721007D1/de
Publication of DE69721007T2 publication Critical patent/DE69721007T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DE69721007T 1996-08-30 1997-09-02 Senkung der heftigkeit einer host-versus-graft-reaktion durch unterdrueckung der hsp60 autoimmunitaet Expired - Lifetime DE69721007T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/706,209 US5993803A (en) 1996-08-30 1996-08-30 Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
PCT/US1997/015294 WO1998008536A2 (en) 1996-08-30 1997-09-02 Method of reducing the severity of host vs. graft reaction by down-regulating hsp60 autoimmunity
US706209 2010-02-16

Publications (2)

Publication Number Publication Date
DE69721007D1 true DE69721007D1 (de) 2003-05-22
DE69721007T2 DE69721007T2 (de) 2004-02-12

Family

ID=24836651

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69721007T Expired - Lifetime DE69721007T2 (de) 1996-08-30 1997-09-02 Senkung der heftigkeit einer host-versus-graft-reaktion durch unterdrueckung der hsp60 autoimmunitaet

Country Status (11)

Country Link
US (1) US5993803A (de)
EP (1) EP0921810B1 (de)
JP (1) JP4256474B2 (de)
AT (1) ATE237344T1 (de)
AU (1) AU722576B2 (de)
CA (1) CA2263816C (de)
DE (1) DE69721007T2 (de)
DK (1) DK0921810T3 (de)
ES (1) ES2198594T3 (de)
IL (2) IL128728A0 (de)
WO (1) WO1998008536A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911772D0 (en) * 1999-05-21 1999-07-21 Semmelweis University Of Medic Diagnosis and treatment of atherosclerosis
CA2394504A1 (en) * 1999-12-15 2001-06-21 Peptor Ltd. Fragments and antagonists of heat shock protein 60
IL150113A0 (en) * 1999-12-15 2002-12-01 Peptor Ltd Fragments and antagonists of heat shock protein 60
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EP1335741A4 (de) * 2000-08-25 2005-10-26 Yeda Res & Dev METHODE ZUR PRÄVENTION VON AUTOIMMUNKRANKHEITEN MIT CpG-ENTHALTENDEN POLYNUCLEOTIDEN(04.03.02)
JP4264257B2 (ja) 2000-11-01 2009-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 熱ショックタンパク質に由来する免疫調節ペプチドとその使用
WO2003063759A2 (en) * 2002-01-31 2003-08-07 Peptor Ltd. Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
WO2003070761A1 (en) * 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
ES2433915T3 (es) * 2002-05-21 2013-12-13 Irun R. Cohen Vacunas de ADN que codifican proteínas de choque térmico
US7494812B2 (en) * 2003-04-01 2009-02-24 University Of Southern California Generation of human regulatory T cells by bacterial toxins for the treatment of inflammatory disorders
CA2547079A1 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
CA2595520A1 (en) 2004-01-28 2005-08-11 Develogen Israel Ltd. Hsp therapy in conjunction with a low antigenicity diet
CU23504A1 (es) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation
CN104203263A (zh) 2012-03-01 2014-12-10 耶达研究与发展有限公司 利用HSP60衍生肽再生胰岛β细胞
WO2013128450A1 (en) 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
EP0503055A1 (de) * 1990-09-06 1992-09-16 Rijksuniversiteit Utrecht Inhibitor der lymphozyten-antwort und immunverwandter krankheiten
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases

Also Published As

Publication number Publication date
EP0921810A2 (de) 1999-06-16
ES2198594T3 (es) 2004-02-01
CA2263816A1 (en) 1998-03-05
ATE237344T1 (de) 2003-05-15
JP4256474B2 (ja) 2009-04-22
IL128728A (en) 2006-09-05
DE69721007T2 (de) 2004-02-12
AU4242697A (en) 1998-03-19
AU722576B2 (en) 2000-08-10
CA2263816C (en) 2008-12-30
WO1998008536A2 (en) 1998-03-05
EP0921810B1 (de) 2003-04-16
US5993803A (en) 1999-11-30
WO1998008536A3 (en) 1998-05-07
IL128728A0 (en) 2000-01-31
DK0921810T3 (da) 2003-07-28
JP2001500488A (ja) 2001-01-16

Similar Documents

Publication Publication Date Title
DE69721007D1 (de) Senkung der heftigkeit einer host-versus-graft-reaktion durch unterdrueckung der hsp60 autoimmunitaet
AU1850597A (en) Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
EP1052866A3 (de) Zugriffskontrollsystem für hochprioritäre Anrufe und/oder Notrufe bei Überlast
BR9406507A (pt) Composição de combustivel ou de lubrificante polt-1-n-alquenaminas e aplicação das mesmas
AU4721696A (en) An osteogenic device and a method for preparing the device
AU2698684A (en) Polypeptide biodegradable et son utilisation pour le relargage progressif de medicaments
MY118995A (en) Oxygen absorption composition
CA2307874A1 (en) Structured voicemail messages
ES2152248T3 (es) Composiciones de colageno de alta concentracion.
NZ312327A (en) Controlling hemipteran insect pests with bacillus thuringiensis
ES2180538T3 (es) Suministro dirigido de vector virico a celulas de mamiferos.
EP1484063A3 (de) Methode, die Abstossung von transplantiertem Gewebe zu verhindern
KR910004173A (ko) 치조농루 예방껌
AU5340001A (en) A method to prevent graft rejection using tgf-beta to induce t suppressor cells
PT766557E (pt) Composicoes de aplicacao topica compreendendo n-acetil-cisteina
GB2364616A (en) Electronic mail systems
KR890007754A (ko) 항체류의 안정화
BG103677A (en) Solid mixtures based on sulphonylcarbamides and adjuvants
GB9108555D0 (en) Improvements in cartridge cases
TW335356B (en) Permselective membranes and methods for their production
AU4561193A (en) Oil additives and compositions
GB9007970D0 (en) Fuel oil compositions
FI964889A0 (fi) Puhekanavan takaisinkytkemisen havannointi
ES2145388T3 (es) Ensayos de antigenos lipopolisacaridos.
WO1999009167A8 (en) Porcine mhc class i genes and uses thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition